Lapatinib Impurity 9(CAS: 231278-84-5)

Lapatinib Impurity 9, with the CAS number 231278-84-5, is a known byproduct or contaminant that may arise during the synthesis of lapatinib, a tyrosine kinase inhibitor used in cancer treatment. It typically has a molecular formula of C19H20N2O4S and is characterized by its structural similarity to the active compound, though it lacks the pharmacological activity. This impurity is often identified through analytical methods such as HPLC and mass spectrometry in pharmaceutical quality control.

Lapatinib Impurity 9 is primarily used in the analysis and characterization of lapatinib in pharmaceutical development and quality assurance processes. It helps in identifying potential impurities during drug manufacturing, ensuring safety and efficacy. Additionally, it serves as a reference standard for research and regulatory compliance in the pharmaceutical industry.

Lapatinib Impurity 9 is not intended for therapeutic use and is generally considered to have lower toxicity compared to lapatinib. However, as with any chemical compound, it should be handled with appropriate safety measures, such as wearing personal protective equipment (PPE), to minimize exposure risks. Safety standards for its handling are typically aligned with those for chemical impurities in pharmaceutical settings.

Lapatinib Impurity 9 should be stored in a cool, dry, and dark place, preferably at 2-8°C. It is important to maintain low humidity and protect it from light exposure to ensure stability. The compound should be kept in a sealed container made of glass or inert material to prevent contamination and degradation over time.